GABA Supplement: Independent Evidence on Stress, Sleep & Safety

Table of contents

• Evidence summary
• What a GABA supplement is
• How it is supposed to work
• GABA supplements are not GABA medicines
• What works and what does not
• Benefits by claim
• Risks and all side effects
• All interactions
• Who should avoid GABA supplements
• Doses studied and product quality
• Follow the money: who makes it and who funded the evidence
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors analysing mostly manufacturer-run trials, or minor declared industry ties; 4 = manufacturer-funded or manufacturer-authored. Credibility runs from A (highest) to D.

The efficacy trials cluster in Japan and South Korea, where GABA foods are a large market, and most were run by sellers. The independent work is mainly European academic research and North American regulators, and it addresses mechanism, cognition and safety rather than stress or sleep.

What a GABA supplement is

Gamma-aminobutyric acid (GABA, chemical name 4-aminobutanoic acid) is an amino acid that the body does not use to build proteins. Health Canada lists it as made synthetically or by fermentation with the bacteria Lentilactobacillus hilgardii or Levilactobacillus brevis, or derived from the kelp Laminaria japonica (Health Canada NHPID). The best-known branded form, PharmaGABA, is made by Pharma Foods International by fermenting L-glutamate with L. hilgardii strain K-3 (GRAS notice GRN 595). "Natural" and synthetic GABA are the same molecule.

GABA also occurs in ordinary foods, including bread, tomatoes, potatoes, melons, cheeses and yoghurts. One novel-food applicant estimated a typical diet supplies about 24 mg a day, though that was the applicant's own figure (FSAI 2010). In Japan, GABA is added to chocolate, drinks, rice and soy sauce. Since 2021 a genome-edited tomato bred for high GABA has been sold there (Nature Biotechnology 2021).

Legal status by country

How it is supposed to work

Inside the brain, GABA is the main "brake" chemical. Medicines that strengthen GABA's action, such as diazepam, reduce anxiety and cause sedation (Valium label). The supplement idea is that swallowing GABA adds to this brake. That depends on three steps, and the evidence for each is very different.

Step 1: absorption into the blood (shown in humans)

Oral GABA is absorbed quickly. In 12 healthy volunteers in Shanghai given 2 g, blood levels peaked within 0.5 to 1 hour, the half-life was about 5 hours, and repeated dosing for 7 days did not cause build-up (Li et al. 2015; funder not verified). A Pharma Foods study found blood GABA peaked 30 minutes after a 100 mg dose (Yamatsu et al. 2016; seller-authored). A Wageningen University study found GABA from pureed tomatoes was absorbed about as well as GABA dissolved in water (de Bie et al. 2022).

Step 2: crossing into the brain (not shown in humans)

This is the weak link. The independent 2015 review found animal studies were contradictory, and found no human study that directly assessed whether GABA crosses the blood–brain barrier. A transporter exists, but the 2015 review found the animal evidence contradictory. The authors knew of no brain-scan (magnetic resonance spectroscopy) study after oral GABA (Boonstra et al. 2015). The 2020 systematic review agreed there were no data on blood–brain barrier passage in humans (Hepsomali et al. 2020). USP concluded that "very low amounts" cross from blood into the brain (USP 2021).

A Université de Sherbrooke trial was registered to test exactly this: 1,800 mg of GABA or placebo in a crossover design with about 30 adults, measuring blood GABA and a brain-stimulation measure of inhibition. At its last update (February 2025) it was not yet recruiting, and we could not confirm whether results have been posted (NCT06464172).

Step 3: effects outside the brain (partly shown, mostly at high doses)

• Pituitary gland: This hormone gland sits outside the blood–brain barrier, so blood GABA could in principle reach it. We found no verified human data on this at usual doses.
• Pancreas: At 2 g, GABA raised insulin and glucagon in healthy volunteers without changing blood glucose (Li et al. 2015).
• Gut–brain signalling: Reviewers suggest any calming effect might work through the gut's own nervous system, but call this unproven (Boonstra 2015). Rodent and cell studies co-authored by Pharma Foods scientists propose vagus nerve and gut-cell routes (Nakamura et al. 2022; Inotsuka et al. 2020). These are laboratory findings only.

In short: absorption into the blood is proven in humans. Entry into the brain, and any calming action there, is not.

GABA supplements are not GABA medicines

Several prescription medicines are described as "GABA drugs", which makes it easy to assume a GABA supplement is a milder version of them. The labels show otherwise.

Two practical points follow. First, trial results for benzodiazepines, pregabalin or gabapentin tell us nothing about GABA supplements. Second, a GABA supplement cannot stand in for these medicines, and must not be used to manage withdrawal from them.

What works and what does not

Benefits by claim

Stress and "relaxation"

The 2020 systematic review included 14 placebo-controlled studies covering stress and sleep; its abstract does not give a per-outcome split, so we do not quote one. Stress outcomes were mainly psychophysiological measures rather than how people felt (Hepsomali et al. 2020). Examples:

• Abdou et al. 2006 (Pharma Foods-authored): 13 people showed more alpha brain waves an hour after GABA. In a second test, 8 people afraid of heights crossed a suspension bridge, 4 per group; saliva IgA fell less after GABA (PubMed).
• Yoto et al. 2012: 63 adults in a single-blind crossover trial took 100 mg GABA or placebo. GABA lessened the drop in brain-wave activity during mental tasks, with matching mood-questionnaire changes (PubMed).
• Kanehira et al. 2011 (Coca-Cola Japan and Pharma Foods authors): 30 people drank 25 or 50 mg GABA in a beverage. The 50 mg drink lowered self-rated mental fatigue, and both doses lowered salivary stress markers (PubMed; J-STAGE affiliations).
• Nakamura et al. 2009 (Ezaki Glico authors): chocolate with 28 mg GABA was linked to quicker heart-rate recovery after an arithmetic task (PubMed).

Boonstra et al. note that most of the supportive stress evidence was reported by researchers with a potential conflict of interest (Boonstra et al. 2015).

What this means: these are short laboratory effects on markers that are not validated measures of real-world stress. None of the trials shows that taking GABA makes daily life less stressful. A 2015 Dutch placebo-controlled trial (Steenbergen et al. 2015) was retracted in 2022 and is not used.

Anxiety

Many products are marketed for anxiety, but we found no placebo-controlled trial of GABA in people diagnosed with generalised anxiety disorder, panic disorder or social anxiety. We could not locate or verify the 2025 Indian comparison trial of GABA, L-theanine and alprazolam that is sometimes cited, so we do not rely on it. For conditions with proven treatments, see our reviews of generalised anxiety disorder and panic disorder.

Sleep and insomnia

The 2020 review found "very limited" evidence for sleep (Hepsomali 2020). The trials in people with insomnia come from one Korean hospital team, both supported by Natural Way Co., which supplied GABA extracted from fermented rice germ:

• Byun et al. 2018: 40 adults with insomnia symptoms were randomised to 300 mg GABA (30 people) or placebo (10 people) for 4 weeks. On overnight sleep studies, time to fall asleep fell from 13.4 to 5.7 minutes and sleep efficiency rose from 79.4% to 86.1%, with both changes reported within the GABA group. The placebo group was only 10 people (full text).
• Yoon et al. 2022: 54 patients were randomised to 75 mg GABA or placebo. Time to fall asleep fell from 9.0 to 4.8 minutes on GABA, but the authors say this was not significant against placebo. Their results table, however, gives a between-group p-value of 0.024, so the sleep-onset result is unclear. Pittsburgh Sleep Quality Index scores improved in both groups (11.2 to 8.7 on GABA; 10.3 to 8.3 on placebo), with no difference between them (full text).

The second trial shows how large the placebo response is in insomnia studies. Note too that in both GABA groups, time to fall asleep was already under 15 minutes at the start, so the measured gains were a few minutes. A Pharma Foods study in 10 to 16 healthy people also reported faster sleep onset on brain-wave recordings after 100 mg (Yamatsu 2016; seller-authored, single-blind).

Other studies add little. A Brazilian trial in 30 overweight women who were also exercising reported better sleep scores after 200 mg a day for 90 days; we could not access its funding statement (Guimarães et al. 2024). A 2026 study of GABA plus L-theanine had no control group (Konno et al. 2026). A 60-person sleep trial sponsored by the Korean company Amorepacific finished in June 2021, but we found no posted results or publication (NCT04857021). For treatments that work, see CBT for insomnia and insomnia.

Blood pressure

Most GABA trials actually tested blood pressure, not stress. USP identified 16 studies of oral GABA, as a supplement or in foods, most of them in mild hypertension (USP 2021):

• Low-salt soy sauce with 120 mg GABA a day lowered systolic pressure by 4.6 mmHg more than control sauces over 12 weeks in 177 untreated people with hypertension. Diastolic pressure did not change.
• A fermented milk containing GABA was tested in 39 adults with mild hypertension in a single-blind, placebo-controlled trial over 12 weeks (Inoue et al. 2003). The abstract reports a significant fall in blood pressure. We could not verify the size of the fall, the GABA dose or the sponsor from the sources we could open, so we give no figure.
• A Japanese trial of GABA-rich Chlorella (20 mg GABA twice daily, 80 people) reported lower systolic pressure than placebo; we did not check its funding (Shimada et al. 2009).

Against this, a Spanish crossover trial of bread rich in GABA found no greater fall in 24-hour blood pressure than ordinary or low-salt bread. It was sponsored and funded by the bread maker Europastry, according to its ISRCTN entry (Becerra-Tomás et al. 2015). A Dutch trial of 500 mg three times daily for 95 days in 52 people with prediabetes found no significant effect on any outcome, including blood pressure, after correction for multiple testing (de Bie et al. 2023; funded by the Dutch public–private Topsector Agri & Food and the Ministry of Economic Affairs). See also our blood pressure supplements review.

Focus, memory and "calm focus"

In 2009 EFSA concluded that no cause-and-effect relationship had been shown between GABA and cognitive function, so no such claim is allowed in the EU (EFSA 2009; as summarised by USP). Independent trials of cognition are few. A Dutch trial (Steenbergen 2015) was retracted in 2022 and is not used. We could not re-check the remaining small trials in full text, so we do not rely on them.

GABA-rich foods

GABA from pureed tomatoes is absorbed about as well as GABA in water (de Bie 2022). That does not show GABA-rich foods work: the food trials above used 2 to 120 mg and measured blood pressure or stress markers, not anxiety or insomnia.

Risks and all side effects

No trial was designed mainly to test GABA's safety, so side-effect data come from small efficacy trials (USP 2021). At typical trial doses, reported effects were mild.

Adverse event reports

USP reports no serious adverse events in the clinical trials it examined. We could not confirm the adverse-event database counts that appear in secondary material, so we do not quote them (USP 2021).

Dependence and withdrawal

We found no study of tolerance, dependence or withdrawal with GABA supplements. The Korean insomnia researchers said larger, longer studies are needed to assess dependence and tolerance (Byun 2018).

All interactions

No formal drug-interaction studies of GABA supplements were found. The table lists what regulators and reviewers flag, and why.

Who should avoid GABA supplements

• Pregnancy and breastfeeding: No studies exist. Health Canada's monograph includes pregnancy and breastfeeding cautions, but the text we could read does not clearly tie them to GABA (monograph).
• Children: We found no published safety data for young children that we could verify.
• Low blood pressure, or taking blood-pressure medicines: because of possible added lowering (USP 2021).
• Liver disease: no data, and one 6-month trial raised a liver-enzyme signal (Hill 2025).
• Epilepsy treated with medicines: possible interaction (USP 2021).
• Kidney disease and surgery: we found no GABA-specific data or regulator advice. Tell your care team about every supplement you take.
• Anyone coming off benzodiazepines, alcohol or other sedatives: GABA has no evidence for withdrawal, and unsupervised withdrawal can be dangerous (Valium label).

Doses studied and product quality

The figures below are doses used in trials or set in official rules. They are not dosing advice.

Canada's permitted range reaches far above the doses used in the trials we could check. That gap matters: the doses many products provide have not been tested for the claims made, while higher doses bring more side effects.

Product quality

• "Natural" versus synthetic: both are the same molecule. "Natural" usually means made by bacterial fermentation (Health Canada NHPID).
• Standards: In 2021 USP found no GABA monograph in the Japanese, European, British, Chinese or WHO pharmacopoeias. Its own proposed monograph would require 98–102% purity and set limits for chloride and sulfate (USP 2021).
• Combination products: Most US adverse-event reports involving GABA concerned multi-ingredient products, which makes problems hard to trace (USP 2021).
• Testing: We found no publicly available independent survey of GABA content in retail products.

Follow the money: who makes it and who funded the evidence

Who makes and sells GABA

• Pharma Foods International Co., Ltd. (Kyoto, Japan): Founded on 12 September 1997, led by chief executive Dr Mujo Kim (company profile). It makes PharmaGABA and is listed on the Tokyo Stock Exchange Prime Market (FISCO company research reports, 2022–2023). It trades under code 2929.
• Natural Way Co. (South Korea): supplied and funded the rice-germ GABA used in both Korean insomnia trials (Yoon 2022).
• Food and drink companies: Ezaki Glico (GABA chocolate) and Coca-Cola (Japan) co-authored trials of their GABA products; a Yakult sponsorship of the 2003 fermented-milk trial could not be verified (Inoue 2003; Nakamura 2009; Kanehira 2011). Otsuka Pharmaceutical made the GABA tablets in one blood-pressure trial (USP 2021).
• Others: Italy's Giuliani SpA applied for EU approval of a GABA-rich ferment (FSAI 2010). Korea's Amorepacific sponsored an unpublished sleep trial (NCT04857021). Sweden's Diamyd Medical developed a slow-release GABA for diabetes (Hill 2025). Tokyo-based Sanatech Seed sells the high-GABA tomato (Nature Biotechnology).

The commercial incentive

Pharma Foods' recent revenue split could not be verified from the sources we opened. In Japan, GABA was the most-used ingredient in Foods with Function Claims in 2023–24, according to a consultancy analysis (NutraIngredients). Sanatech's technology chief told Nature Biotechnology that more than 400 GABA-enriched foods and drinks were on the Japanese market, a figure from a company with a GABA product to sell (Nature Biotechnology). We found no independent, citable figure for global GABA sales.

Who funded the evidence

• Stress and sleep trials: 11 of the 14 trials in the main review had a company-employed author. The review's own lead author worked for Unilever, and the other three declared various industry fees (Hepsomali 2020). Independent reviewers found most evidence for a calming effect came from researchers with a potential conflict (Boonstra 2015).
• Health Canada's relaxation claim: cites Kanehira 2011 and Abdou 2006, both with Pharma Foods authors (monograph).
• Independent work: a Dutch cognition trial (not re-checked in full text), the Wageningen prediabetes trial (public–private Dutch funding), the Chinese pharmacokinetic study (funder not verified) and the Swedish trial (public funders plus Diamyd). None tested stress or anxiety as its main outcome.

Documented regulatory and integrity events

• Two withdrawn FDA GRAS notices. In 2008 Pharma Foods asked FDA to accept GABA as safe in beverage bases, chewing gum, ready-to-drink coffee and tea, and candy (GRN 257). In 2015 it sought the same for foods and drinks at 100 mg a serving (GRN 595). Both were closed at the company's request, on 22 December 2008 (GRN 257) and 10 November 2015 (GRN 595) (GRN 257; GRN 595).
• FDA correspondence. FDA's internal correspondence on these notices was released under freedom-of-information rules and published by the Environmental Defense Fund, an advocacy group (EDF 2021). We could not read the released PDFs with the tools used for this review, so this article does not rely on any reviewer comments. FDA reached no final finding.
• Japan's notification system. Foods with Function Claims are not individually approved by the government (Consumer Affairs Agency). After the 2024 Kobayashi Pharmaceutical red yeast rice scandal, which did not involve GABA, Japan required companies from September 2024 to report health harms and new findings, with manufacturing standards due from September 2026 (NutraIngredients).
• Unpublished trial. The Amorepacific sleep trial (60 people, completed 2021) has no posted results that we could find (NCT04857021).
• No enforcement actions found. We found no FDA warning letter, recall or court action about GABA itself.

What this means: The case for GABA as a stress or sleep aid was built mainly by companies selling GABA ingredients and GABA-enriched foods, using small, short trials with surrogate outcomes. Regulators have been cautious: the EU allows no claim, FDA was never asked to finish a review for everyday foods, and Canada's relaxation claim rests on company-linked studies. The independent research that does exist has not confirmed a calming effect, and it has raised open questions about brain entry and long-term safety.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Stress, anxiety and depression supplements: evidence and safety
• Sleep supplements: evidence limits, product quality and safety
• L-theanine (often combined with GABA)
• Glycine for sleep
• Magnesium
• Valerian
• Generalised anxiety disorder
• Cognitive behavioural therapy for insomnia
• Blood pressure supplements

GABA-acting prescription medicines (not the same as GABA supplements):

• Pregabalin
• Diazepam
• Alprazolam

Frequently asked questions

Sources and funding notes

What we could not verify. The EFSA 2009 opinion's full text was blocked to automated access, so we relied on its title and on USP's summary of its conclusion. We could not find a current EU Novel Food Catalogue entry for GABA, and the EUR-Lex copy of the Union list (consolidated August 2026) could not be opened, so its EU novel-food status is unconfirmed. We found no UK-specific decision on GABA. Australia's status is reported from USP (2021) and was not rechecked against the current Permissible Ingredients Determination. We could not open the full texts of Abdou 2006, Yoto 2012 and Yamatsu 2016. We relied on their abstracts and on two reviews for design details and author affiliations. We could not access the Japanese-language Kajimoto and soy sauce trials, which are described here via USP. We did not check the funding of Shimada 2009, and could not access the funding statement of Guimarães 2024. We found no publication of the Amorepacific trial (NCT04857021). USP's financial pages blocked automated access, so the statement about its revenue relies on USP's own published summary as shown in search results. PharmaGABA revenue and global GABA market size are not publicly reported in any source we could verify. We could also not verify the 2025 Indian GABA, L-theanine and alprazolam trial, the Pharma Foods listing year, the Pharma Foods FY2026 segment figures, the 2003 fermented-milk blood-pressure figures, the adverse-event database counts, or a rat brain-uptake figure once attributed to Boonstra et al. These points are removed from the text. In this review, the 2015 Dutch trial (Steenbergen et al.) was found to be retracted in 2022 (Scientific Reports) and is no longer used. The FDA correspondence PDFs could not be read, so no reviewer quotes are used. The Byun 2018 figures come from a search summary because the full text was blocked. The soy-sauce and bread blood-pressure figures, the de Bie 2023 details, the Becerra-Tomás funding, the Altınok 2023, Leonte 2018 and Hara 2025 details were not re-checked against full text. The Yoon et al. 2022 table (p = 0.024 between groups) conflicts with the authors' wording, and we report both.

1. Hepsomali P et al. Effects of oral GABA administration on stress and sleep in humans: a systematic review. Front Neurosci 2020 (full text) — main systematic review; lead author employed by Unilever, (fee not verified); co-authors declared varied industry fees.
2. Boonstra E et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol 2015 (full text) — blood–brain barrier and conflicts; Dutch NWO grant; no conflicts declared.
3. Oketch-Rabah HA et al. USP safety review of GABA. Nutrients 2021 (full text) — safety, regulation, adverse events; no external funding; authors from USP, NIH Office of Dietary Supplements and Procter & Gamble.
4. USP financial overview — USP describes its main revenue as sales of reference standards and publications.
5. US FDA GRAS Notice Inventory, GRN 257 (GABA) — US regulator; notifier Pharma Foods International; closed 22 December 2008 at the notifier's request.
6. US FDA GRAS Notice Inventory, GRN 595 (GABA) and FDA response letter — US regulator; closed 10 November 2015 at the notifier's request.
7. GRN 257 notice with FDA correspondence and GRN 595 notice with FDA correspondence — FDA documents released under FOIA, hosted by the Environmental Defense Fund.
8. Environmental Defense Fund, Broken GRAS (December 2021) — US advocacy non-profit; context for the FOIA documents.
9. Health Canada NNHPD, Cognitive Function Products monograph (30 January 2026) — Canadian regulator; GABA claim, doses, cautions.
10. Health Canada Natural Health Products Ingredients Database: gamma-aminobutyric acid — Canadian regulator; sources and classification.
11. EFSA NDA Panel. Health claims related to GABA and cognitive function (ID 1768). EFSA Journal 2009 — EU regulator.
12. Food Safety Authority of Ireland. Safety assessment of BIOGABA (application accepted 2010) — Irish regulator; applicant Giuliani SpA.
13. EU Implementing Regulation 2017/2470, Union list of novel foods (consolidated 10 August 2026) — EU law; the text could not be opened, so GABA's listing status here is unconfirmed.
14. Consumer Affairs Agency (Japan). Outline of food labelling systems for health and nutrition — Japanese regulator.
15. NutraIngredients (September 2024): GABA tops Japan's FFC ingredients — trade press reporting a Smooth Link Inc. consultancy analysis.
16. NutraIngredients (July 2024): new FFC rules after the Kobayashi scandal — trade press.
17. Byun JI et al. GABA from fermented rice germ in insomnia. J Clin Neurol 2018 (full text) — South Korea; supported by Natural Way Co., which supplied the GABA.
18. Yoon S et al. Low-dose GABA from unpolished rice germ for sleep. J Clin Neurol 2022 (full text) — South Korea; supported by Natural Way Co.
19. Yamatsu A et al. Oral GABA, sleep and absorption. Food Sci Biotechnol 2016 — all authors at Pharma Foods International.
20. Abdou AM et al. Relaxation and immunity effects of GABA. BioFactors 2006 — first author at Pharma Foods International.
21. Yoto A et al. Oral GABA, mood and brain activity under mental stress. Amino Acids 2012 — University of Shizuoka; identified by Boonstra et al. as including an author affiliated with the GABA maker.
22. Kanehira T et al. GABA beverage and occupational fatigue. J Nutr Sci Vitaminol 2011 (J-STAGE) — authors from Coca-Cola (Japan), Pharma Foods International and University of Shizuoka.
23. Nakamura H et al. GABA-enriched chocolate and stress. Int J Food Sci Nutr 2009 — first author at Ezaki Glico.
24. Hara Y et al. GABA and esports performance. Nutrients 2025 — Pharma Foods International affiliation (funding statement not found); all authors named inventors on a related patent application.
25. Inoue K et al. GABA fermented milk in mild hypertension. Eur J Clin Nutr 2003 (journal page) — authors and sponsor details could not be verified in our searches.
26. Shimada M et al. GABA-rich Chlorella and blood pressure. Clin Exp Hypertens 2009 — Japan; funding not checked.
27. Becerra-Tomás N et al. Functional bread rich in GABA and blood pressure. Medicine 2015 — Spain; sponsor and funder Europastry per ISRCTN; author employment not verified.
28. de Bie TH et al. GABA supplementation in prediabetes. Am J Clin Nutr 2023 — Wageningen University; Topsector Agri & Food and Dutch Ministry of Economic Affairs (AF17048).
29. de Bie TH et al. Bioavailability of GABA from tomatoes. Food Funct 2022 — Wageningen University.
30. Li J et al. GABA in healthy volunteers: pharmacokinetics and pharmacodynamics. Front Pharmacol 2015 — Fudan University, China; funder not verified.
31. Hill H et al. Long-term GABA treatment in type 1 diabetes. Sci Rep 2025 (full text) — Uppsala University; Swedish public and charity funders plus Diamyd Medical; no competing interests declared.
32. Martin A et al. Oral GABA in children with new-onset type 1 diabetes. Nat Commun 2022 — US; JDRF, NIH, Diamyd Medical and Janssen per the UAB release; GABA supplier not verified.
33. Steenbergen L et al. GABA and action selection. Sci Rep 2015 (retracted 2022) (full text) — Leiden University; NWO and DFG grants.
34. Leonte A et al. GABA and temporal attention. Brain Cogn 2018 — Groningen and Leiden universities.
35. Altınok A et al. GABA, working memory and attention. J Psychopharmacol 2023 — University of Groningen; no financial support; no conflicts.
36. Guimarães AP et al. GABA in sedentary overweight women. J Diet Suppl 2024 — Federal University of Ouro Preto, Brazil; funding not accessed.
37. Konno H et al. GABA plus L-theanine and sleep (single-arm). Eur Rev Med Pharmacol Sci 2026 — Japan; one author listed a Nestlé email address.
38. Nakamura U et al. Dietary GABA and vagal afferent nerves. Nutrients 2022 and Inotsuka R et al. GABA and gut-cell exosomes. Food Funct 2020 — laboratory studies with Pharma Foods co-authors.
39. ClinicalTrials.gov NCT06464172 — Université de Sherbrooke trial of oral GABA and brain GABA; not yet recruiting at last update.
40. ClinicalTrials.gov NCT04857021 — Amorepacific-sponsored GABA sleep trial; completed 2021; no results posted.
41. Valium (diazepam) prescribing information, DailyMed — FDA-approved label.
42. Lyrica (pregabalin) prescribing information, DailyMed — FDA-approved label.
43. Neurontin (gabapentin) prescribing information, DailyMed — FDA-approved label.
44. FDA. FDA acts on dietary supplements containing DMHA and phenibut (April 2019) — US regulator.
45. Waltz E. GABA-enriched tomato is first CRISPR-edited food to enter market. Nature Biotechnology 2021 — news report; quotes Sanatech Seed.
46. Pharma Foods International company profile and company history — company sources.

Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.